Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Intraoperative tumor localization and resection can be enhanced using intraoperative
fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is
expressed on > 95% of colorectal cancers.. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW
is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal
carcinomatosis of colorectal cancer.